NCT03478462: Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma |
|
|
| Active, not recruiting | 1 | 30 | Canada, US, RoW | CLR 131, I-131-CLR1404 | Cellectar Biosciences, Inc. | Pediatric Solid Tumor, Pediatric Lymphoma, Pediatric Brain Tumor, DIPG, Neuroblastoma, Ewing Sarcoma, Rhabdomyosarcoma, Osteosarcoma | 09/22 | 12/24 | | |
